{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Horak F, Zieglmayer P, Zieglmayer R, Lemell P, et al. The CRTH2 antagonist OC000459', 'reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised,', 'placebo-controlled, double-blind trial. Allergy 2012;67:1572-1579.', 'Kato A. Group 2 innate lymphoid cells in airway diseases. Chest 2019;156:141-149.', 'Kuiper JR, Hirsch AG, Bandeen-Roche K, et al. Prevalence, severity, and risk factors for acute', 'exacerbations of nasal and sinus symptoms by chronic rhinosinusitis status. Allergy', '2018;73(6):1244-1253', 'Kupczyk, M. and Kuna, P. Targeting the PGD2/CRTH2/DP1 Signaling pathway in asthma and', 'allergic disease: current status and future perspectives. Drugs 2017;77:1281-129', 'Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993;31:183-184.', 'Meltzer E01, Hamilos DL, Hadley JA, et al. Rhinosinusitis: developing guidance for clinical', 'trials. J Allergy Clin Immunol 2006;118(5 Suppl):S17-61.', 'MHRA, Guidance: Managing clinical trials during Coronavirus (COVID-19) 2020.', ' https://www.gov.uk/guidance/managing-clinical-trials-during-coronavirus-covid-19.Accessed', 'April 13, 2020.', 'Ortega H, Fitzgerald M, Bhakta N, Raghupathi K, Singh D. Reduction of exhaled nitric oxide by', 'the DP2 antagonist GB001 in patients with mild atopic asthma. J Allergy Clin Immunol.', '2019a;143(2):AB104.', 'Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult', 'sinusitis. Otolaryngol Head Neck Surg 2015;152(2 Suppl):S1-S39.', 'Rothenberg ME, Saito H, Peebles RS. Advances in mechanisms of allergic disease in 2016. J', 'Allergy Clin Immunol 2017;140:1622-1631', 'Scadding G, Hellings P, Alobid I, Bachert C, Fokkens W, Van Wijk RG, et al. Diagnostic tools', 'in Rhinology EAACI position paper. Clin Transl Allergy 2011:2;1-39.', 'Singh D, Ravi A, Southworth T. CRTH2 antagonists in asthma: current perspectives. Clin', 'Pharmacol 2017;9:165-173.', 'Skolnick BE, Ortega H, Raghupathi K, Tompkins C, Fitzgerald M, Singh D. Markers of', 'eosinophilic inflammation are associated with response to the DP2 antagonist GB001. American', 'Rhinologic Society Annual Meeting; September 13-14, 2019; New Orleans, LA.', 'Tan BK, Klingler AI, Poposki JA, Stevens WW, Peters AT, Suh LA, et al. Heterogeneous', 'inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J', 'Allergy Clin Immunol 017;139:699-703.', 'Thomas M, Yawn BP, Price D, Lund V, Mullol J, Fokkens W. EPOS Primary Care Guidelines:', 'European position paper on the primary care diagnosis and management of rhinosinusitis and', 'nasal polyps 2007 - a summary. Primary Care Respiratory Journal 2008; 17:79-89.', 'Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory', 'endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin', 'Immunol 2016;137:1449-1456.', '92', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'van Agthoven M1, Fokkens WJ, van de Merwe JP, Marijke van Bolhuis E, Uyl-de Groot CA,', 'Busschbach JJ. Quality of life of patients with refractory chronic rhinosinusitis: effects of', 'filgrastim treatment. Am J Rhinol. 2001;15:231-237.', '93', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}